Business Segments · Intangible asset impairment charge
Pharmaceuticals — Intangible asset impairment charge
This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2023
Last reportedQ4 2025
Rolls up toIndefinite-Lived Intangible Asset Impairment
How to read this metric
An increase signals that previous investments or acquisitions are underperforming or have lost commercial viability.
Detailed definition
Non-cash charges recognized when the carrying value of an intangible asset, such as acquired intellectual property or li...
Peer comparison
Commonly reported by peers as 'Impairment of Intangible Assets'.
Metric ID:
vrtx_segment_pharmaceuticals_intangible_asset_impairment_chargeHistorical Data
12 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $379.00M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | — | — | — | — | — | — | — | — | -100.0% | — | — |
Range$0.00 – $379.00M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pharmaceuticals — intangible asset impairment charge?
- Vertex Pharmaceuticals (VRTX) reported pharmaceuticals — intangible asset impairment charge of $0.00 in Q4 2025.
- What does pharmaceuticals — intangible asset impairment charge mean?
- A write-down in the value of intangible assets like patents or acquired drug rights.